Funding for this research was provided by:
National Center for Advancing Translational Sciences (UL1 TR000454, UL1 TR000135, UL1 TR000064)
Mayo Foundation for Medical Education and Research
National Institute of Health Pharmacogenetics Research Network (U01-GM074492)
National Institutes of Health Pharmacogenetics Research Network (U19-GM061388, U19-GM061390)
Text and Data Mining valid from 2018-06-20
Received: 19 November 2017
Accepted: 25 May 2018
First Online: 20 June 2018
Ethics approval and consent to participate
: All study participants from PEAR and PEAR-2 (NCT00246519, NCT01203852 ExternalRef removed ) provided written informed consent. The Institutional Review Boards at participating clinical trial sites including the University of Florida, Mayo Clinic, and Emory University approved both PEAR and PEAR-2. The studies were conducted in accordance with the principles of the Declaration of Helsinki and the US Code of the Federal Regulations for Protection of Human Subjects.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.